Real-world study of Imjudo and Imfinzi in South Korea
Part of Cancer, Digestive system clinical trials.
This study collects information on how well Imjudo and Imfinzi work in real-world settings for patients who are prescribed these drugs as part of standard care in South Korea. It helps doctors understand how these treatments perform outside of clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor has prescribed Imjudo or Imfinzi for a condition that is approved for use in South Korea
- You are not currently in another clinical trial testing an experimental drug
- You are willing to give written permission (informed consent) to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
This study looks at how patients with certain conditions are doing while taking Koselugo (selumetinib) in real life. It's a way to gather information about the treatment's effectiveness and safety outside of a controlled clinical trial.
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This study is checking the safety of ozanimod, a daily pill, for people with moderate to severe active ulcerative colitis. It looks at how well patients tolerate the medicine in real-world use in Korea.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.